Using human antibodies to fight cytomegalovirus infections
Official title: Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
Funded at Icahn School of Medicine at Mount Sinai · NIH-10867639 · Data updated 2026-11-12
This study is working on creating new treatments using special antibodies to help protect people, especially those with weakened immune systems and newborns, from cytomegalovirus (CMV) infections, aiming to offer a safer and more effective option than current antiviral medications.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 19, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $683,927 |
| NIH project number | 1R56AI174062-01A1 |
| Project ID | NIH-10867639 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include pregnant women at risk of CMV infection and immunocompromised individuals who are more susceptible to severe CMV disease.
✕Less likely to help
Patients who are not affected by CMV or do not have conditions that compromise their immune systems may not benefit from this research.
What this research studies
This research focuses on developing human monoclonal antibodies to combat cytomegalovirus (CMV), a virus that can cause serious health issues, particularly in immunocompromised individuals and newborns. The study aims to create effective treatments that can prevent CMV infection and its spread by targeting specific viral proteins. By optimizing the use of these antibodies, the researchers hope to provide a safer alternative to existing antiviral drugs, which have significant limitations. Patients may benefit from a new therapeutic option that is both effective and has a better safety profile.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the incidence of CMV-related birth defects and improve outcomes for immunocompromised patients.
How similar studies have gone: Previous research has shown promise in using monoclonal antibodies for viral infections, indicating that this approach could be effective for CMV as well.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Tortorella, Domenico — Icahn School of Medicine at Mount Sinai
- Study coordinator: Tortorella, Domenico
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.